Kaiser Permanente, Aurora, CO, USA.
Ann Pharmacother. 2011 Apr;45(4):485-91. doi: 10.1345/aph.1P628. Epub 2011 Apr 12.
Quality guidelines recommend avoidance of skeletal muscle relaxants in patients 65 years and older, but this recommendation is based on expert opinion, not evidence.
To describe an elderly population using skeletal muscle relaxants and compare the incidence of physical injury among these patients before and after initiation of the medication.
This was a retrospective, pre-post cohort analysis, with each patient serving as his/her own control. In a population of elderly patients who purchased a prescription for a skeletal muscle relaxant, the primary outcome was to compare the proportion of patients experiencing an injury in a 60-day period prior to initiating the drug to the proportion experiencing an injury in the 60 days immediately following the purchase date.
Of the 11,875 patients included in the study, 108 (0.9%) experienced an injury during the baseline period and 144 (1.2%) experienced an injury in the 60-day follow-up period (unadjusted OR 1.35; 95% CI 1.05 to 1.75; adjusted OR 1.35; 95% CI 1.01 to 1.81). A total of 333 patients needed to be treated with a skeletal muscle relaxant to result in 1 additional injury. Independent predictors of an injury included a history of an injury in the previous 6 months (OR 3.01; 95% CI 1.54 to 5.88) and older age (OR 1.06; 95% CI 1.04 to 1.09).
The absolute increase in risk of injury in this population using a skeletal muscle relaxant was small but statistically significant. Cautionary use of these medications in the elderly continues to be advisable, but their use in selected patients 65 years and older could be considered if the expected benefits outweigh the small increased risk of injury. More study is needed to quantify the benefits versus risks of these medications in this population.
质量指南建议避免 65 岁及以上患者使用骨骼肌松弛剂,但这一建议是基于专家意见,而非证据。
描述使用骨骼肌松弛剂的老年人群,并比较这些患者在开始使用药物前后发生身体损伤的发生率。
这是一项回顾性、前后队列分析,每位患者自身作为对照。在购买骨骼肌松弛剂处方的老年患者人群中,主要结局是比较患者在开始用药前 60 天内发生损伤的比例与在购买日期后 60 天内发生损伤的比例。
在研究的 11875 名患者中,108 名(0.9%)在基线期发生损伤,144 名(1.2%)在 60 天随访期发生损伤(未调整 OR 1.35;95%CI 1.05 至 1.75;调整 OR 1.35;95%CI 1.01 至 1.81)。需要治疗 333 名患者使用骨骼肌松弛剂才能导致 1 例额外损伤。损伤的独立预测因素包括 6 个月内的损伤史(OR 3.01;95%CI 1.54 至 5.88)和年龄较大(OR 1.06;95%CI 1.04 至 1.09)。
在使用骨骼肌松弛剂的人群中,损伤风险的绝对增加很小,但具有统计学意义。在老年人中谨慎使用这些药物仍然是明智的,但如果预期的益处超过小的损伤风险增加,在选定的 65 岁及以上患者中使用这些药物可以考虑。需要进一步研究来量化这些药物在该人群中的益处与风险。